In a study released Monday by the Integrated Benefits Institute, researchers found that due to lost time from work caused by the novel coronavirus disease 2019 (COVID-19), employee benefits for absent workers could cost employers more than $23 billion.
In a study released today by the Integrated Benefits Institute (IBI), researchers found that due to lost time from work caused by the coronavirus disease 2019 (COVID-19), employee benefits for absent workers could cost employers more than $23 billion in total.
As indicated in the study, up to 5.6 million employees could be impacted during the pandemic if efforts to curb the spread prove insignificant, with almost 3 million workers at firms with fewer than 500 employees entitled to paid leave per the Families First Coronavirus Response Act (FFCRA) that went into effect on April 1, 2020. For employees at large companies (>500 employees), strategies by organizations to ensure coverage could prove vital.
“One important thing to keep in mind is that however the pandemic plays out—whether that is 1.5 million infected employees, 5 million or something else—about half of employees at large companies won’t have the income protection afforded by disability insurance or FFCRA,” said Brian Gifford, PhD, Director, Research and Analytics for IBI.
In the analysis, researchers derived employment, wage, and leave benefit data from the US Bureau of Labor Statistics, and additionally examined lost workday experiences contained in IBI’s own data set of employer-sponsored short-term disability (STD) claims. They formed a model for lost work time impacts for low-, mid-, and high-range scenarios depending on the total COVID-19 cases nationwide (≤4 million, ≤8 million, and ≤ 15 million cases, respectively).
Findings from the model suggest that employers and their disability insurance partners will be affected by substantial lost work time costs, with Thomas Parry, PhD, president of IBI, indicating that STD claims are “estimated to take between 20-75% of the premiums collected in 2018 due to the growing number of US employees diagnosed with COVID-19.”
While the significance of the findings depends on the eventual severity of the virus, researchers note that from March 17-31, confirmed cases increased by an average of 30% per day, which would mean that at the current rate the United States would diagnose its 4 millionth case by mid-April. Additionally, Parry notes that the study findings represent a very conservative estimate of COVID-19—related lost work time costs and exclude costs pertaining to paid family leave.
“Even if employees have some sick days to fall back on, on top of everything else, they’re going to lose about $2000 in earnings if they contract coronavirus. That’s not only going to impact the US workforce, but also consumer spending when businesses try to restart after the pandemic,” said Gifford.
To assist employers, researchers also provided guidance from healthcare and absence management professionals, which addresses areas such as:
Employers Shift to Equity-Focused Strategies as Health Costs Outpace Wages
October 31st 2024As health care costs escalate, a new survey reveals that 74% of employers are grappling with the impact on employee wages and benefits, with many anticipating further cost-shifting to their workforce.
Read More
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen
Key Issues Influencing 2022 Employer Health Care Strategy and Plan Design
August 31st 2021On this episode of Managed Care Cast, we speak with Ellen Kelsay, president and CEO of the Business Group on Health, on the findings from her organization's 2022 Large Employers’ Health Care Strategy and Plan Design Survey.
Listen
Prescription Rebate Guarantees: Employer Insights
July 19th 2024This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy benefits manager selection.
Read More
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More